Development of a High-Retention Ocular Gel for Prolonged Intraocular Pressure Control using Timolol Maleate
Abstract
The objective of this study was to develop and evaluate a sustained-release gel system for Timolol Maleate to overcome the limitations of conventional eye drops, such as rapid nasolacrimal drainage and poor ocular bioavailability in the management of glaucoma. Formulations were prepared using various concentrations of mucoadhesive polymers and evaluated for critical parameters including clarity, pH, drug content, and rheological behavior. The gels exhibited a physiological pH and pseudoplastic flow, ensuring both ocular compatibility and ease of administration. In-vitro release studies in simulated tear fluid (pH 7.4) demonstrated that the optimized formulation provided a controlled drug delivery profile over a period of several hours, significantly extending the residence time compared to standard aqueous solutions. Kinetic modeling indicated that the drug release followed a diffusion-controlled mechanism, suggesting that this gel system could successfully reduce dosing frequency, minimize systemic side effects, and improve patient compliance in the long-term treatment of intraocular hypertension.
Keywords: Timolol Maleate, Glaucoma, Ocular Drug Delivery, Sustained Release
Keywords:
Timolol Maleate, Glaucoma, Ocular drug delivery, Gel, Sustained ReleaseDOI
https://doi.org/10.22270/jddt.v16i5.7729References
1. Quigley HA, Broman AT. Number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-7. https://doi.org/10.1136/bjo.2005.081224 PMid:16488940 PMCid:PMC1856963
2. Awwad S, Mohamed Ahmed AHA, Sharma G, Heng JS, Khaw PT, Brocchini S, et al. Sustained release of Timolol maleate from a thermo-responsive gel. Int J Pharm. 2017;523(1):127-34.
3. Gaudana R, Ananthula HK, Parenti A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-60. https://doi.org/10.1208/s12248-010-9183-3 PMid:20437123 PMCid:PMC2895432
4. Alany RG. Ocular drug delivery: a difficult road to ride. Pharm Dev Technol. 2017;22(3):303.
5. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol. 2013;2(2):47-64. https://doi.org/10.5497/wjp.v2.i2.47 PMid:25590022 PMCid:PMC4289909
6. Kaur IP, Smith MJ. In-situ gels as drug delivery systems. Drug Dev Ind Pharm. 2011;37(10):1121-30.
7. Rathore KS. In-situ gelling ophthalmic drug delivery systems: An approach to maximize ocular bioavailability. Open Ophthalmol J. 2020;14:45-53.
8. Banker GS, Rhodes CT. Modern Pharmaceutics. 4th ed. New York: Marcel Dekker; 2002. https://doi.org/10.1201/9780824744694 PMCid:PMC6758410
9. Almeida H, Amaral MH, Lobão P, Lobo JMS. In situ gelling systems: a strategy to improve ocular bioavailability. Drug Discov Today. 2014;19(12):1881-9. https://doi.org/10.1016/j.drudis.2013.10.001 PMid:24120893
10. Bisht R, Jaiswal AK, Rupenthal ID. In situ gel-forming systems for corneal drug delivery. In: Ocular Drug Delivery Systems. Elsevier; 2020. p. 41-65.
11. British Pharmacopoeia. London: The Stationery Office; 2023.
12. Kurniawansyah IS, et al. Characteristics and Antibacterial Activity of Chloramphenicol In Situ Gels. J Pharm Bioallied Sci. 2020;12(Suppl 2):S794-8.
13. Cho H, et al. Development of a Timolol-loaded in situ gelling system for glaucoma treatment. J Pharm Investig. 2018;48(5):543-51.
14. Stable Micro Systems. Measure mucoadhesion/bioadhesion | Texture Analyser Test. [Online]. Available from: https://stablemicrosystems.com/MeasureMucoadhesion.html
15. Bisht R, Jaiswal AK, Rupenthal ID. In situ gel-forming systems for corneal drug delivery. In: Ocular Drug Delivery Systems. Elsevier; 2020. p. 41-65.
16. DB-ALM Protocol n° 96: Hen's Egg Test on the Chorioallantoic Membrane (HET-CAM). European Union Reference Laboratory for alternatives to animal testing; 2023.
17. Gaudana R, Ananthula HK, Parenti A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348-60. https://doi.org/10.1208/s12248-010-9183-3 PMid:20437123 PMCid:PMC2895432
18. International Council for Harmonisation (ICH). Stability Testing of New Drug Substances and Products Q1A(R2); 2003
Published
Abstract Display: 0 
PDF Downloads: 0 PDF Downloads: 0 How to Cite
Issue
Section
Copyright (c) 2026 Himanshi Verma, Shashank Waghe, Navdeep Jaiswal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.